• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CARDINAL HEALTH SANTA CLARA MYNX CONTROL; DEVICE, HEMOSTASIS, VASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CARDINAL HEALTH SANTA CLARA MYNX CONTROL; DEVICE, HEMOSTASIS, VASCULAR Back to Search Results
Catalog Number MX5060E
Device Problem Premature Activation (1484)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 11/28/2023
Event Type  malfunction  
Event Description
As reported, the sealant protection distal tip of a 5f mynx control vascular closure device (vcd) was broken and the device could not enter the 5f non-cordis sheath.Therefore, the product was not available and manual compression was performed for twenty minutes and recovered.There was no reported patient injury.The mynx control vessel closure unit was prepared and used in accordance with instructions for use (ifu).There were no visible signs of device/package damage prior to use.The femoral artery¿s suitability was verified on angiography, including the insertion angle (30~45 degrees) of the 5f non-cordis vascular sheath introducer.The vessel diameter was verified to be greater than 5mm in diameter.The puncture site did not have visible calcium/plaque.There was no vessel tortuosity.There was no stent near the puncture site.The vessel did not have stenosis >50% at the puncture site.The target femoral site was not previously closed with any closure less than thirty days prior to this procedure.There was no evidence of pre-existing hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to use mynx control.The mynx vcd used in transfemoral cerebral angiography (tfca) with a retrograde approach.The physician achieved certification on the use of mynx and has used the device several times prior to this procedure.Other procedural details were requested but are unknown, unavailable, not answered, or not applicable.The device will be returned for evaluation.Addendum: product evaluation revealed that the sealant remained in the manufacturing position exposed due to the conditions of the sealant outer sleeve assembly that presented damaged evidence that could be related to the reported event.Visual inspection at high magnification, showed that the sealant outer sleeve assembly damaged evidence that could be described as a frayed/split/torn condition.
 
Manufacturer Narrative
Complaint conclusion: as reported, the sealant protection distal tip of a 5f mynx control vascular closure device (vcd) was broken and the device could not enter the 5f non-cordis sheath.Therefore, the product was not available and manual compression was performed for twenty minutes and recovered.There was no reported patient injury.The mynx control vessel closure unit was prepared and used in accordance with instructions for use (ifu).There were no visible signs of device/package damage prior to use.The femoral artery¿s suitability was verified on angiography, including the insertion angle (30-45 degrees) of the 5f non-cordis vascular sheath introducer.The vessel diameter was verified to be greater than 5mm in diameter.The puncture site did not have visible calcium/plaque.There was no vessel tortuosity.There was no stent near the puncture site.The vessel did not have stenosis >50% at the puncture site.The target femoral site was not previously closed with any closure less than thirty days prior to this procedure.There was no evidence of pre-existing hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to use mynx control.The mynx vcd used in transfemoral cerebral angiography (tfca) with a retrograde approach.The physician achieved certification on the use of mynx and has used the device several times prior to this procedure.Other procedural details were requested but are unknown, unavailable, not answered, or not applicable.A non-sterile mynx control vascular closure device 5f involved in the reported complaint was returned for investigation.Visual inspection of the received device showed that button 1 and button 2 were not depressed.The sealant remained in its manufactured position exposed due to the conditions of the sealant outer sleeve assembly that presented evidence of damage that could be related to the reported event.The exposed sealant condition resulted in a swelled sealant condition that was completely covered in blood.The sheath used in the procedure was not returned with the device to be evaluated.Dimensional analysis of the slit length could not be measured due to the conditions of the observed device.A functional test for introduction/withdrawal into the catheter sheath introducer (csi) could not be executed due to the conditions of the sealant sleeves.Additionally, due to the exposure condition observed with the sealant that could be concluded as premature deployment malfunction, a deployment mechanism simulation was performed.During the deployment simulation, the device received showed that the deployment mechanism was not compromised.After depressing button 1 and 2 in the unit, the sealant was deployed and the balloon was fully retracted as expected, per the unit¿s intended use mechanism.Per microscopic analysis, visual inspection at high magnification showed that the sealant outer sleeve assembly damages could be described as a frayed/split/torn condition.The reported event of ¿sealant sleeves (cartridge assembly)-damaged¿ was confirmed through analysis of the returned device as the sealant sleeve assembly had a condition observed as ¿sealant sleeves (cartridge assembly)-frayed/split/torn.¿ additionally, a condition was noted in the returned device of ¿mynx control system-deployment difficulty-premature¿ due to the exposed sealant from the damaged sleeves.The exact cause of the observed conditions could not be conclusively determined during analysis.Based on the information available for review and product analysis, it is difficult to determine what factors may have contributed to the issue experienced.However, procedural/handling factors (such as using excessive force during insertion into the sheath), and/or the condition of the sheath (although not returned) possibly contributed to the damaged condition of the sealant sleeves, the impedance experienced during insertion, and the subsequent premature exposure of the sealant.It should be noted that the mynx control device is manufactured with a slit at the end of the catheter cartridge tubing.The outer sleeve assembly is assembled with 2 side slit overlapping outer sleeves.The sealant is placed right under the outer sleeve assembly and is protected from exposing prematurely.The slits on the outer sleeve assembly are designed to decrease unsheathing force and increase deployment reliability.Refer to the diagram of the mynx control vcd within the ifu displaying the sealant sleeve with slit.If the outer sleeve is damaged/shredded during prepping phase and/or insertion into sheath, it could cause the sealant to be exposed/swollen prematurely and/or obstruct the device path and prevent the device from being inserted into the procedural sheath.As warned in the ifu, which is not intended as a mitigation, ¿do not use if components or packaging appear to be damaged or defective or if any portion of the packaging has been previously opened.¿ additionally, the ifu states ¿step 1: position balloon, insert the mynx control vcd into the procedural sheath through the sheath valve.Advance the catheter until the sheath catch nears the hub of the sheath.Rotate the sheath catch as needed to hook onto the side port of the procedural sheath.¿ neither the product analysis, nor the information available for review suggest that the failures could be related to the design or manufacturing process of the unit.Therefore, no corrective/preventative actions will be taken at this time.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MYNX CONTROL
Type of Device
DEVICE, HEMOSTASIS, VASCULAR
Manufacturer (Section D)
CARDINAL HEALTH SANTA CLARA
5452 betsy ross drive
santa clara CA 95054
Manufacturer (Section G)
CORDIS US CORP.
14201 nw 60 avenue
miami lakes FL 33014
Manufacturer Contact
karla castro
5452 betsy ross drive
santa clara, CA 95054
7863138372
MDR Report Key19003285
MDR Text Key338896264
Report Number3004939290-2024-00154
Device Sequence Number1
Product Code MGB
Combination Product (y/n)N
Reporter Country CodeKS
PMA/PMN Number
P040044
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,Company Representative
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/29/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberMX5060E
Device Lot NumberF2324903
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer01/08/2024
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 03/13/2024
Initial Date FDA Received03/29/2024
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured09/26/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
5F TERUMO SHEATH
-
-